<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04830345</url>
  </required_header>
  <id_info>
    <org_study_id>CBA-PLN-002</org_study_id>
    <nct_id>NCT04830345</nct_id>
  </id_info>
  <brief_title>Phase 3 Study to Compare the Efficacy and Safety of Botulinum Toxin at Moderate to Severe Glabellar Lines</brief_title>
  <official_title>A Multicenter, Double-blind, Randomized, Parallel, Active-controlled, Non-inferiority, Phase 3 Clinical Trial to Compare the Efficacy and Safety of ATGC-100 Versus Botox in Subjects With Moderate to Severe Glabellar Lines</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>EuBiologics Co.,Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>EuBiologics Co.,Ltd</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Efficacy and safety of ATGC-100 are assessed in subjects with moderate to severe glabellar&#xD;
      lines.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">June 29, 2020</start_date>
  <completion_date type="Anticipated">September 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients with improvement of glabellar lines at maximum frown</measure>
    <time_frame>4 weeks post injection compared to baseline</time_frame>
    <description>Improvement rate of glabellar lines at maximum frown with Physician's Facial wrinkle scale (FWS)</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">290</enrollment>
  <condition>Glabellar Frown Lines</condition>
  <arm_group>
    <arm_group_label>ATGC-100 100U</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ATGC-100 will be injected to 5 glabellar lines (each 4U/0.1mL; total 20U) at Day 0</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Botox 100U</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Botox inj. will be injected to 5 glabellar lines (each 4U/0.1mL; total 20U) at Day 0</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ATGC-100 100U</intervention_name>
    <description>Clostridium botulinum toxin type A</description>
    <arm_group_label>ATGC-100 100U</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Botox 100U</intervention_name>
    <description>Clostridium botulinum toxin type A</description>
    <arm_group_label>Botox 100U</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Healthy male and female aged 19 to 65 years old&#xD;
&#xD;
          2. Participants with Facial Wrinkle Scale (FWS) score of &gt; 2 at maximum frown at&#xD;
             screening&#xD;
&#xD;
          3. Participants willing to follow the study procedures and schedules&#xD;
&#xD;
          4. Participants willing to give written informed consent to participate in the trial&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Participants with severe glabellar lines that cannot be improved physical method&#xD;
&#xD;
          2. Pregnant, lactating women or women of childbearing age not using a reliable method of&#xD;
             contraception&#xD;
&#xD;
          3. Participants with known hypersensitivity to any component of the study drug&#xD;
&#xD;
          4. Participant who has skin disorder including infection and scar on injection site&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Nowon Eulji University Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 31, 2021</study_first_submitted>
  <study_first_submitted_qc>April 1, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 5, 2021</study_first_posted>
  <last_update_submitted>April 1, 2021</last_update_submitted>
  <last_update_submitted_qc>April 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

